Peptide questions · Pemvidutide
Pemvidutide side effects: what studies and users report
Reviewed Evidence: ModeratePublished by PepVault
The side effects most commonly reported for pemvidutide are nausea, vomiting and constipation, among 4 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: pemvidutide is investigational and has no label yet.
What is commonly reported with pemvidutide
- Nausea
- Vomiting
- Constipation
- Diarrhea
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Nausea | 21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more |
| Vomiting | 18: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 14 more |
| Constipation | 13: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 9 more |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |

Model. Individual results vary.
Which pemvidutide side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Every effect on pemvidutide’s list also appears for at least one other metabolic & GLP-1 compound, so nothing on it is pemvidutide’s own.
What the pemvidutide safety notes say
The library’s safety note
Pemvidutide is investigational and has no label yet. In the 48-week MOMENTUM obesity trial (391 adults without diabetes; results reported by the company), nausea affected 25.5%, 59.6% and 51.5% on 1.2, 1.8 and 2.4 mg vs 11.3% on placebo, and vomiting 6.1%, 27.3% and 27.8% vs 3.1%, mostly mild to moderate; side effects led 5.1%, 19.2% and 19.6% to stop vs 6.2% on placebo, most within the first 16 weeks. There were no major cardiac events, cardiac side effects matched placebo, and average heart rate rose by about 3 beats per minute at most. In the IMPACT trial in people with MASH, 0% (1.2 mg) and 1.2% (1.8 mg) stopped for side effects over 48 weeks vs 3.5% on placebo. Until it has a label, the approved GLP-1 class cautions (thyroid C-cell tumors in rodents, pancreatitis, gallbladder disease) are the reference point. Discuss with your clinician.
The library’s interaction note
No interaction results have been published (a drug-interaction study in healthy volunteers, NCT04972396, is registered as completed). Approved GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed, and add to the glucose-lowering of insulin or sulfonylureas; pemvidutide hasn't been characterized for either. In MOMENTUM, fasting glucose and HbA1c didn't change in people without diabetes. It is a GLP-1 drug itself, so it is not stacked with another one. Discuss all your medicines with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the pemvidutide reports come from
The library rates the evidence on pemvidutide as moderate: animal studies plus some human data.
Of the library’s 7 research notes on pemvidutide, 6 rest on randomized trials and 1 on community reports.
Our 4 study pages on pemvidutide: 3 randomized trials and 1 animal study (mice).
So pemvidutide has controlled trials in people to set its listed effects against.
What our pemvidutide study pages report on safety
Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trial
Randomized trial, human, 2026: Nausea was the most common side effect, in 22% of the 1.2 mg arm, 41% of the 1.8 mg arm and 17% of the placebo arm, and no severe or serious side effects were judged to be caused by the drug. In people with MASH and stage F2 or F3 fibrosis, liver fat and non-invasive liver markers kept improving on pemvidutide through 48 weeks, with nausea more common in the higher-dose arm.
Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLD
Randomized trial, human, 2025: Body weight fell by 6.2% over the 24 weeks, and side effects were uncommon at all doses.
Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeks
Randomized trial, human, 2025: Side effects, mostly mild or moderate, were reported in 78% and 81% of the pemvidutide arms versus 67% on placebo. Stopping because of side effects was rare: none of the 41 patients on 1.2 mg, 1 of 85 on 1.8 mg and 2 of 86 on placebo.
Questions people ask
What are the side effects of pemvidutide?
The side effects most commonly reported for pemvidutide are nausea, vomiting and constipation, among 4 the library lists; the library’s evidence on it includes controlled trials in people.
Do pemvidutide’s side effects come from human studies?
The library rates the evidence on pemvidutide as moderate, and the library’s evidence on it includes controlled trials in people.
Which pemvidutide side effects are its own?
None: each effect the library lists for pemvidutide is listed for at least one other metabolic & GLP-1 compound too.
Does pemvidutide interact with other medicines?
The library’s interaction note on pemvidutide begins: No interaction results have been published (a drug-interaction study in healthy volunteers, NCT04972396, is registered as completed).